<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00997594</url>
  </required_header>
  <id_info>
    <org_study_id>274</org_study_id>
    <secondary_id>No secondary IDs</secondary_id>
    <nct_id>NCT00997594</nct_id>
  </id_info>
  <brief_title>Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation</brief_title>
  <official_title>Changes in Adrenal Hormones During Adrenal Radiofrequency Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mie University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mie University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate changes in adrenal hormones during adrenal
      radiofrequency (RF) ablation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adrenal radiofrequency (RF) ablation has been increasingly used for the treatment of
      unresectable adrenal tumors. But one of the major complication is a increase in blood
      pressure. Hormonal release during RF ablation is considered the cause of hypertension. But
      there has been no evidence that adrenal hormones affects changes in blood pressure. In this
      prospective study, we evaluate the changes in adrenal hormones during RF ablation and clarify
      the cause of hypertensive crisis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in Catecholamine</measure>
    <time_frame>One day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Cathecholamine Levels</measure>
    <time_frame>around one year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Hypertension During Adrenal or Non-adrenal Radiofrequency Ablation</measure>
    <time_frame>1 week</time_frame>
    <description>Blood pressure was monitored during radiofrequency (RF) ablation. The frequency of hypertension (systolic blood pressure of more than 200 mmHg) was evaluated and compared between the adrenal and non-adrenal (RF ablation other than adrenal gland) RF ablation groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in Cortisol</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Adrenal Tumors</condition>
  <arm_group>
    <arm_group_label>Adrenal radiofrquency (RF) ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who wll receive adrenal RF ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abdominal RF ablation other than adrenal gland</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who will receive abdominal radiofrequency ablation other than adrenal gland.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency ablation</intervention_name>
    <description>Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.</description>
    <arm_group_label>Adrenal radiofrquency (RF) ablation</arm_group_label>
    <arm_group_label>Abdominal RF ablation other than adrenal gland</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable adrenal tumor which will be treated by radiofrequency (RF)ablation

          -  Blood pressure is 140mmHg or less before RF ablation

          -  Age of 20-years or more

          -  Performance status of 0 or 1

          -  Agreement from the patient

        Exclusion Criteria:

          -  Platelet count of 50,000/mm^3 or International normalized ratio (INR)&gt;1.5
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koichiro Yamakado, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mie University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2009</study_first_posted>
  <results_first_submitted>October 27, 2010</results_first_submitted>
  <results_first_submitted_qc>January 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2011</results_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mie University</investigator_affiliation>
    <investigator_full_name>Koichiro Yamakado</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>adrenal gland</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adrenal Radiofrequency Ablation</title>
          <description>Patients who received adrenal radiofrequency (RF) ablation.</description>
        </group>
        <group group_id="P2">
          <title>Abdominal Radiofrequency Ablation Other Than Adrenal Gland</title>
          <description>Patients who received radiofrequency (RF) ablation other than adrenal gland such as liver and kidney.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completion of Ablation Procedure</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adrenal Radiofrequency Ablation</title>
          <description>Patients who received adrenal radiofrequency (RF) ablation.</description>
        </group>
        <group group_id="B2">
          <title>Abdominal Radiofrequency Ablation Other Than Adrenal Gland</title>
          <description>Patients who received radiofrequency (RF) ablation other than adrenal gland such as liver and kidney.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="13"/>
                    <measurement group_id="B2" value="71" spread="12"/>
                    <measurement group_id="B3" value="65" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Increase in Catecholamine</title>
        <time_frame>One day</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increase in Cortisol</title>
        <time_frame>1 day</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Cathecholamine Levels</title>
        <time_frame>around one year</time_frame>
        <posting_date>10/2015</posting_date>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Hypertension During Adrenal or Non-adrenal Radiofrequency Ablation</title>
        <description>Blood pressure was monitored during radiofrequency (RF) ablation. The frequency of hypertension (systolic blood pressure of more than 200 mmHg) was evaluated and compared between the adrenal and non-adrenal (RF ablation other than adrenal gland) RF ablation groups.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adrenal Radiofrequency Ablation</title>
            <description>Patients who received adrenal radiofrequency (RF) ablation.</description>
          </group>
          <group group_id="O2">
            <title>Abdominal Radiofrequency Ablation Other Than Adrenal Gland</title>
            <description>Patients who received radiofrequency (RF) ablation other than adrenal gland such as liver and kidney.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hypertension During Adrenal or Non-adrenal Radiofrequency Ablation</title>
          <description>Blood pressure was monitored during radiofrequency (RF) ablation. The frequency of hypertension (systolic blood pressure of more than 200 mmHg) was evaluated and compared between the adrenal and non-adrenal (RF ablation other than adrenal gland) RF ablation groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Just a comparison of the percentage of hypertension between the 2 patient groups.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week to 1 year (mean, 215 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adrenal Radiofrequency Ablation</title>
          <description>Patients who received adrenal radiofrequency (RF) ablation.</description>
        </group>
        <group group_id="E2">
          <title>Abdominal Radiofrequency Ablation Other Than Adrenal Gland</title>
          <description>Patients who received radiofrequency (RF) ablation other than adrenal gland such as liver and kidney.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small patient series is one of limitations of this study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Koichiro Yamakado</name_or_title>
      <organization>Mie University</organization>
      <phone>+81-59-231-5029 ext 5630</phone>
      <email>yama@clin.medic.mie-u.ac.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

